A new look at toxicity in the era of precision oncology: Imaging findings, their relationship with tumor response, and effect on metastasectomy

American Journal of Roentgenology

Volumn 207, Issue 1, 2016, Pages 4-14

  Holler Howard, Stephanie A ^a,b   Krajewski, Katherine M ^a,b   Jagannathan, Jyothi P ^a,b   Braschi Amirfarzan, Marta ^a,b   Tirumani, Sree H ^a,b   Shinagare, Atul B ^a,b   Ramaiya, Nikhil H ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adverse events; Biomarker; Metastasectomy; Toxicity

Indexed keywords

ANGIOGENESIS INHIBITOR; CORTICOSTEROID; CRIZOTINIB; DACARBAZINE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; IPILIMUMAB; IRINOTECAN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NIVOLUMAB; OXALIPLATIN; PAZOPANIB; PLACEBO; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ASCITES; CANCER CONTROL; COLITIS; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATTY LIVER; HEPATITIS; HEPATOMEGALY; HUMAN; HYPERTENSION; HYPOPHYSITIS; HYPOPITUITARISM; IMMUNE EVASION; IMMUNOPATHOLOGY; JAUNDICE; KIDNEY CARCINOMA; LIFE EXTENSION; LIVER DISEASE; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; LUNG METASTASIS; LUNG RESECTION; LUNG TOXICITY; LYMPHADENOPATHY; MEDICAL DECISION MAKING; MELANOMA; META ANALYSIS (TOPIC); METASTASIS RESECTION; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; ONCOLOGIST; ONCOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PERIPORTAL EDEMA; PERSONALIZED MEDICINE; PHYSICIAN ATTITUDE; PNEUMONIA; PRECISION ONCOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOLOGIST; REVIEW; RISK BENEFIT ANALYSIS; SARCOMA; STEATOSIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; METASTASIS; NEOPLASMS;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DIAGNOSTIC IMAGING; HUMANS; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; NEOPLASMS; PRECISION MEDICINE;

EID: 84979037027     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.15.15480     Document Type: Review

References (66)

1. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011; 103:117-128
2. Howard SA, Krajewski KM, Weissman BN, Seltzer SE, Ramaiya NH, Van den Abbeele AD. Cancer imaging training in the 21st century: an overview of where we are, and where we need to be. J Am Coll Radiol 2015; 12:714-720
3. Dabydeen DA, Jagannathan JP, Ramaiya N, et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 2012; 48:1519-1524
4. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103:763-773
5. Liu HB, Wu Y, Lv TF, et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and metaanalysis. PLoS One 2013; 8:e55128
6. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13(22 Pt 1):6681-6688
7. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25:4575-4580
8. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309-318; discussion, 318-321
9. U.S. Department of Health and Human Services, National Cancer Institute, Cancer Therapy Evaluation Program, Common toxicity criteria manual, version 2.0. Published June 1, 1999
10. U.S. Department of Health and Human Services, National Institutes of Health (NIH), National Cancer Institute. Common Terminology Criteria for Adverse Events, version 4.03. NIH website. evs.nci. nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14- QuickReference-5x7.pdf. Published May 28, 2009. Updated June 14, 2010. Accessed March 3, 2016
11. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723
12. Nishino M, Tirumani SH, Ramaiya NH, Hodi FS. Cancer immunotherapy and immune-related response assessment: the role of radiologists in the new arena of cancer treatment. Eur J Radiol 2015; 84:1259-1268
13. Howard SA, Rosenthal MH, Jagannathan JP, et al. Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology. AJR 2015; 204:919-932
14. Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR 2011; 197:[web] W992-W1000
15. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with met-astatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-6053
16. Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2015; 3:1185-1192
17. Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab-associated colitis: CT findings. AJR 2013; 200:[web]W468-W474
18. Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 2009; 218:69-70
19. Chao HS, Chang CP, Chiu CH, Chu LS, Chen YM, Tsai CM. Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib. Clin Nucl Med 2009; 34:346-349
20. Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 2015; 373:288-290
21. Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 2013; 31:1071-1077
22. Hunter G, Voll C, Robinson CA. Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci 2009; 36:518-520
23. Brandi G, Venturi M, Dika E, Maibach H, Patrizi A, Biasco G. Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy? Cutan Ocul Toxicol 2013; 32:336-338
24. Min JH, Lee HY, Lim H, et al. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol 2011; 68:1099-1109
25. Seet RC, Rabinstein AA. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM 2012; 105:69-75
26. Seet RC, Rabinstein AA, Lindell PE, Uhm JH, Wijdicks EF. Cerebrovascular events after bevacizumab treatment: an early and severe complication. Neurocrit Care 2011; 15:421-427
27. Wang W, Zhao LR, Lin XQ, Feng F. Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer. World J Gastroenterol 2014; 20:6691-6697
28. Delyon J, Maio M, Lebbe C. The ipilimumab lesson in melanoma: achieving long-term survival. Semin Oncol 2015; 42:387-401
29. Johnson DB, Friedman DL, Berry E, et al. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immunol Res 2015; 3:464-469
30. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18:2039-2047
31. O'Regan KN, Jagannathan JP, Ramaiya N, Hodi FS. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR 2011; 197:[web]W241-W246
32. Min L, Vaidya A, Becker C. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract 2012; 18:351-355
33. Bacanovic S, Burger IA, Stolzmann P, Hafner J, Huellner MW. Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET/CT. Clin Nucl Med 2015; 40:e518-e519
34. van der Hiel B, Blank CU, Haanen JB, Stokkel MP. Detection of early onset of hypophysitis by 18F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab. Clin Nucl Med 2013; 38:e182-e184
35. Min L, Ibrahim N. Ipilimumab-induced autoimmune adrenalitis. Lancet Diabetes Endocrinol 2013; 1:e15
36. Lack EE. Lymphoid "hypophysitis" with end organ insufficiency. Arch Pathol 1975; 99:215-219
37. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235:759-766
38. Jamison RL, Donohue JH, Nagorney DM, Rosen CB, Harmsen WS, Ilstrup DM. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997; 132:505-510; discussion, 511
39. Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer: a comparison with resective treatment. Ann Surg 1984; 199:502-508
40. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065-2072
41. Khan AZ, Morris-Stiff G, Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg 2009; 16:137-144
42. Wolf PS, Park JO, Bao F, et al. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. J Am Coll Surg 2013; 216:41-49
43. Howard SA, Krajewski KM, Thornton E, et al. Decade of molecular targeted therapy: abdominal manifestations of drug toxicities-what radiologists should know. AJR 2012; 199:58-64
44. Viswanathan C, Truong M, Sagebiel T, Garg N, Bhosale P. Imaging of chemotherapy-related iatrogenic abdominal and pelvic conditions. Radiol Clin North Am 2014; 52:1029-1040
45. Mortele KJ, Ros PR. Imaging of diffuse liver disease. Semin Liver Dis 2001; 21:195-212
46. Hamer OW, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB. Fatty liver: imaging patterns and pitfalls. RadioGraphics 2006; 26:1637-1653
47. Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998; 2:292-298
48. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000; 191:38-46
49. Gomez D, Malik HZ, Bonney GK, et al. Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis. Br J Surg 2007; 94:1395-1402
50. Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H. CT findings of chemotherapyinduced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 2011; 258:41-56
51. Erturk SM, Mortele KJ, Binkert CA, et al. CT features of hepatic venoocclusive disease and hepatic graftversus-host disease in patients after hematopoietic stem cell transplantation. AJR 2006; 186:1497-1501
52. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15:460-466
53. Neeff HP, Drognitz O, Klock A, et al. Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases. Int J Colorectal Dis 2012; 27:635-645
54. Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 2013; 36:491-503
55. Maki RG. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist 2007; 12:999-1006
56. Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008; 109:329-334
57. Binder D, Hubner RH, Temmesfeld-Wollbruck B, Schlattmann P. Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials. Cancer Chemother Pharmacol 2011; 68:1575-1583
58. Chi DC, Brogan F, Turenne I, Zelonis S, Schwartz L, Saif MW. Gemcitabine-induced pulmonary toxicity. Anticancer Res 2012; 32:4147-4149
59. Yakabe T, Kitahara K, Komiya K, et al. Severe eosinophilic pneumonia presenting during gemcitabine adjuvant chemotherapy. World J Surg Oncol 2013; 11:167
60. Ljungberg B. The role of metastasectomy in renal cell carcinoma in the era of targeted therapy. Curr Urol Rep 2013; 14:19-25
61. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011; 117:2873-2882
62. Kow AW, Kwon CH, Song S, Kim JM, Joh JW. Clinicopathological factors and long-term outcome comparing between lung and peritoneal metastasectomy after hepatectomy for hepatocellular carcinoma in a tertiary institution. Surgery 2015; 157:645-653
63. Yoon YS, Kim HK, Kim J, et al. Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol 2010; 17:2795-2801
64. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology 2009; 23:488-496
65. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526
66. Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2:632-642